S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
LXEO · Lexeo Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Lexeo Therapeutics Inc (LXEO)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$3.02
-0.00
(-0.17%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$3.02
$2.97
$3.08
52-WEEK RANGE
$3.02
$2.55
$10.99
What's happening
- LXEO is down 0.17% today, trading at $3.02. — Live quote
- Volume today (75,486) is well below its 3-month average of 1,218,720. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.30 actual vs. $-0.29 estimated (-3.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 8
Buy 7
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (16 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
LXEO
-69.59%
vs S&P 500
-82.36%
1-YEAR RETURN
LXEO
-67.25%
vs S&P 500
-81.81%
6-MONTH RETURN
LXEO
-54.10%
3-MONTH RETURN
LXEO
-35.19%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.30
Est. $-0.29
MISS -3.2%
2026-04-26 (Q1 2026)
$-0.25
Est. $-0.32
BEAT +21.8%
2026-01-26 (Q4 2025)
$-0.27
Est. $-0.32
BEAT +15.8%
2025-10-26 (Q3 2025)
$-0.33
Est. $-0.53
BEAT +37.8%
Valuation Measures & Ratios
Enterprise Value4$155.7M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)535.16
Price / Book71.55
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin-11991.84%
Operating Margin-12408.36%
Return on Equity (ROE8)-41.85%
Return on Assets (ROA9)-38.03%
Avg Volume (3M)1,218,720
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $400.9M | $462.9M | $407.5M | $177.1M | $114.0M |
| P/E | -4.34 | -4.66 | -3.75 | -1.62 | -1.08 |
| Price/Book | 1.71 | 2.00 | 3.37 | 1.28 | 1.29 |
| ROE | -39.33% | -42.87% | -89.82% | -79.21% | -119.24% |
| ROA | -36.27% | -39.64% | -75.45% | -62.18% | -83.59% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short19,246,976
Change from Prior Settlement-6.69%
% of Float—
Days to Cover (Short Ratio)9.04
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-09-29; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -11991.8%. Finnhub fundamentals ↗
- Trailing 52-week price return is -67.2%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on LXEO
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Operating income | -$28.0M | -$22.3M | -$21.6M | -$30.7M | -$33.8M | -$31.5M | -$23.6M | -$23.3M |
| Net income | -$25.9M | -$20.2M | -$20.3M | -$26.1M | -$32.7M | -$29.5M | -$21.2M | -$21.7M |
| EPS (diluted) | $-0.30 | $-0.25 | $-0.33 | $-0.60 | $-0.99 | $-0.89 | $-0.64 | $-0.77 |
| EPS (basic) | $-0.30 | $-0.25 | $-0.33 | $-0.60 | $-0.99 | $-0.89 | $-0.64 | $-0.77 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $254.9M | $250.4M | $268.7M | $143.8M | $176.1M | $125.7M | $146.9M | $173.9M |
| Total liabilities | $19.8M | $18.9M | $22.0M | $23.0M | $37.9M | $37.6M | $30.1M | $34.5M |
| Stockholders' equity | $235.1M | $231.5M | $246.7M | $120.8M | $138.2M | $88.1M | $116.8M | $139.3M |
| Total current assets | $217.9M | $200.9M | $188.4M | $127.8M | $140.1M | $105.3M | $126.1M | $159.5M |
| Total current liabilities | $15.7M | $14.2M | $16.8M | $17.3M | $31.6M | $30.8M | $22.8M | $26.8M |
| Cash & equivalents | $92.8M | $71.8M | $63.0M | $41.0M | $35.5M | $28.9M | $35.0M | $157.0M |
| Marketable securities (current) | — | — | — | — | — | $70.9M | $86.5M | — |
| Other current assets | — | — | — | — | — | — | — | — |
| Marketable securities (non-current) | — | — | — | — | — | $7.0M | $7.0M | — |
| Property, plant & equipment | $1.1M | $1.1M | $1.1M | $1.2M | $1.1M | $1.0M | $1.0M | $1.2M |
| Accounts payable | $4.2M | $3.3M | $4.9M | $4.7M | $20.0M | $12.0M | $6.4M | $8.4M |
| Common stock & paid-in capital | $8.0K | $7.0K | $7.0K | $5.0K | $5.0K | $3.0K | $3.0K | $3.0K |
| Retained earnings | -$426.2M | -$400.3M | -$380.1M | -$359.2M | -$338.9M | -$312.8M | -$280.2M | -$254.2M |
| Accumulated other comprehensive income (loss) | -$298.0K | -$142.0K | $188.0K | $89.0K | -$13.0K | -$54.0K | -$103.0K | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$17.6M | -$21.1M | -$20.1M | -$29.5M | -$27.2M | -$21.7M | -$28.3M | -$17.8M |
| Investing cash flow | $14.3M | $27.5M | -$101.7M | $35.0M | -$39.2M | $15.6M | -$93.6M | -$83.0K |
| Financing cash flow | $24.4M | $2.5M | $143.8M | $52.0K | $73.0M | $11.0K | -$97.0K | -$72.0K |
| Free cash flow | -$17.6M | -$21.2M | -$20.1M | -$29.8M | -$27.3M | — | -$28.3M | -$17.9M |
| Capital expenditures | $7.0K | $35.0K | $0 | $289.0K | $108.0K | — | $0 | $83.0K |
| Share-based compensation | $5.7M | $2.8M | $2.7M | $2.7M | $3.1M | $3.7M | $3.5M | $3.8M |
| Change in accounts payable | $828.0K | -$1.6M | $200.0K | -$15.3M | $8.4M | $5.1M | -$2.0M | $2.7M |
| Purchases of investments | $12.0M | — | $140.0M | $0 | $55.4M | — | $93.6M | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Revenue | — | — | — | $654.0K |
| Operating income | -$109.3M | -$105.8M | -$68.5M | -$60.5M |
| Net income | -$100.0M | -$98.3M | -$66.4M | -$59.3M |
| EPS (diluted) | $-1.86 | $-3.09 | $-12.40 | $-36.36 |
| EPS (basic) | $-1.86 | $-3.09 | $-12.40 | $-36.36 |
| Operating margin | — | — | — | -$9.3K |
| Net margin | — | — | — | -$9.1K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $268.7M | $146.9M | $139.8M | $97.1M | — |
| Total liabilities | $22.0M | $30.1M | $26.3M | $25.0M | — |
| Stockholders' equity | $246.7M | $116.8M | $113.5M | -$113.0M | -$55.6M |
| Total current assets | $188.4M | $126.1M | $124.3M | $80.0M | — |
| Total current liabilities | $16.8M | $22.8M | $17.2M | $14.3M | — |
| Cash & equivalents | $63.0M | $35.0M | $121.5M | $77.3M | $135.9M |
| Marketable securities (current) | — | $86.5M | — | — | — |
| Other current assets | — | — | $3.0K | $371.0K | — |
| Marketable securities (non-current) | — | $7.0M | — | — | — |
| Property, plant & equipment | $1.1M | $1.0M | $1.1M | $998.0K | — |
| Accounts payable | $4.9M | $6.4M | $3.8M | $2.7M | — |
| Common stock & paid-in capital | $7.0K | $3.0K | $3.0K | $0 | — |
| Retained earnings | -$380.1M | -$280.2M | -$181.8M | -$115.4M | — |
| Accumulated other comprehensive income (loss) | $188.0K | -$103.0K | — | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Operating cash flow | -$98.6M | -$81.2M | -$59.5M | -$54.6M |
| Investing cash flow | -$90.3M | -$94.1M | -$165.0K | -$901.0K |
| Financing cash flow | $216.8M | $88.8M | $103.8M | $189.0K |
| Free cash flow | -$99.0M | -$81.6M | -$59.6M | -$55.2M |
| Capital expenditures | $397.0K | $481.0K | $115.0K | $672.0K |
| Share-based compensation | $12.1M | $12.5M | $3.0M | $1.8M |
| Change in accounts payable | -$1.6M | $2.4M | -$180.0K | -$426.0K |
| Purchases of investments | $195.4M | $93.6M | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding LXEO as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-02-18 to 2026-09-14
Recent transactions
- Insiders have net sold 70,970 shares over the last 182 days, across 0 purchases and 9 sales.
- Most recent: Bhalla Narinder Pal (Chief Medical Officer) — Grant / award of 2,714 shares on 2026-09-14.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)70,970 sh(9 txns)
Net Shares-70,970
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Bhalla Narinder Pal | Chief Medical Officer | Grant / award | 2026-09-14 | 2,714 |
| Otero Jose Manuel | Chief Operating Officer | Grant / award | 2026-09-14 | 2,110 |
| Townsend Richard Nolan | Chief Executive Officer | Grant / award | 2026-09-14 | 2,306 |
| Tamayo Louis Edward | Chief Financial Officer | Open market sale | 2026-08-18 | 4,117 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | Bhalla Narinder Pal | Chief Medical Officer | Grant / award | 2,714 | $3.58 |
| 2026-09-14 | Otero Jose Manuel | Chief Operating Officer | Grant / award | 2,110 | $2.64 |
| 2026-09-14 | Townsend Richard Nolan | Chief Executive Officer | Grant / award | 2,306 | $2.64 |
| 2026-08-18 | Tamayo Louis Edward | Chief Financial Officer | Open market sale | 4,117 | $4.91 |
| 2026-08-18 | Townsend Richard Nolan | Chief Executive Officer | Open market sale | 3,345 | $4.95 |
| 2026-08-18 | Otero Jose Manuel | Chief Operating Officer | Open market sale | 1,304 | $4.96 |
| 2026-07-01 | Tamayo Louis Edward | Chief Financial Officer | Open market sale | 4,641 | $4.49 |
| 2026-07-01 | Otero Jose Manuel | Chief Operating Officer | Open market sale | 4,666 | $4.48 |
| 2026-07-01 | Bhalla Narinder Pal | Chief Medical Officer | Open market sale | 22,306 | $4.42 |
| 2026-07-01 | Townsend Richard Nolan | Chief Executive Officer | Open market sale | 25,947 | $4.48 |
| 2026-06-29 | Tamayo Louis Edward | Chief Financial Officer | Grant / award | 12,000 | $0.00 |
| 2026-06-29 | Otero Jose Manuel | Chief Operating Officer | Grant / award | 12,060 | $0.00 |
| 2026-06-29 | Bhalla Narinder Pal | Chief Medical Officer | Grant / award | 55,000 | $0.00 |
| 2026-06-29 | Townsend Richard Nolan | Chief Executive Officer | Grant / award | 67,000 | $0.00 |
| 2026-05-18 | Otero Jose Manuel | Chief Operating Officer | Open market sale | 1,302 | $5.07 |
| 2026-05-18 | Townsend Richard Nolan | Chief Executive Officer | Open market sale | 3,342 | $5.06 |
| 2026-04-06 | Townsend Richard Nolan | Chief Executive Officer | Open market sale | 55,000 | $5.69 |
| 2026-03-13 | Townsend Richard Nolan | Chief Executive Officer | Grant / award | 2,623 | $2.64 |
| 2026-03-13 | Otero Jose Manuel | Chief Operating Officer | Grant / award | 5,930 | $2.64 |
| 2026-02-18 | Otero Jose Manuel | Chief Operating Officer | Open market sale | 3,016 | $6.40 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:35 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-29 | 8-K | 2026-09-29 | View on SEC.gov → |
| 2026-09-28 | 4 | 2026-09-24 | View on SEC.gov → |
| 2026-09-28 | 4 | 2026-09-24 | View on SEC.gov → |
| 2026-09-28 | 4 | 2026-09-24 | View on SEC.gov → |
| 2026-09-28 | 4 | 2026-09-24 | View on SEC.gov → |
| 2026-09-22 | 8-K | 2026-09-16 | View on SEC.gov → |
| 2026-08-19 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-08-19 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-08-19 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-08-12 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-12 | 8-K | 2026-08-12 | View on SEC.gov → |
| 2026-07-01 | 4 | 2026-06-29 | View on SEC.gov → |
Recent news
Headlines about LXEO (Lexeo Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy Transcript
Seeking Alpha · 2026-10-21 -
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM
Yahoo Finance · 2026-10-19 -
Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
Yahoo Finance · 2026-10-08 -
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)
Yahoo Finance · 2026-10-01 -
Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia
Yahoo Finance · 2026-09-23 -
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
Yahoo Finance · 2026-09-23 -
Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript
Seeking Alpha · 2026-09-22 -
Lexeo Therapeutics, Inc. (LXEO) Mantle Therapeutics Inc. - M&A Call - Slideshow
Seeking Alpha · 2026-09-22
No headlines in this category right now — try “All”.